International Journal of Antimicrobial Agents
Volume 36, Issue 1 , Pages 28-32 , July 2010

Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres

  • Helio S. Sader

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    • Federal University of Sao Paulo, São Paulo, Brazil
    • Corresponding Author InformationCorresponding author at: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. Tel.: +1 319 665 3370; fax: +1 319 665 3371.
    • ,
  • David J. Farrell

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    • ,
  • Ronald N. Jones

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    • Tufts University School of Medicine, Boston, MA, USA

Received 11 November 2009 ,Accepted 7 March 2010.

References 

  1. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373–1406
  2. European Antimicrobial Resistance Surveillance System. http://www.rivm.nl/earss/about [accessed 6 April 2010].
  3. World Health Organization . WHO global strategy for containment of antimicrobial resistance. Geneva, Switzerland: WHO; 2001;WHO/CDS/CSR/DRS/2001/2/EN [accessed 6 April 2010] http://www.who.int/csr/resources/publications/drugresist/en/EGlobal_Strat.pdf
  4. Clinical Laboratory Standards Institute . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed.. Wayne, PA: CLSI; 2009;[Document M07-A8]
  5. Clinical Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Wayne, PA: CLSI; 2009;[Document M100-S19]
  6. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee . EUCAST technical note on daptomycin. Clin Microbiol Infect. 2006;12:599–601
  7. Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2007;28:1047–1053
  8. Moore CL, Hingwe A, Donabedian SM, Perri MB, Davis SL, Haque NZ, et al. Comparative evaluation of epidemiology and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) USA300 infections causing community- and healthcare-associated infections. Int J Antimicrob Agents. 2009;34:148–155
  9. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681
  10. Chamberlain RS, Culshaw DL, Donovan BJ, Lamp KC. Daptomycin for the treatment of surgical site infections. Surgery. 2009;146:316–324
  11. Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs. 2007;67:1483–1512
  12. Seaton RA. Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother. 2008;62(Suppl. 3):iii15–iii23
  13. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49:177–180
  14. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (≥8mg/kg) daptomycin therapy. Ann Pharmacother. 2009;43:1211–1219
  15. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill. 2008;13:pii: 19046
  16. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135–142
  17. Ross JE, Fritsche TR, Sader HS, Jones RN. Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. Int J Antimicrob Agents. 2007;29:295–301
  18. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009;59(Suppl. 1):S59–S74
  19. Sader HS, Moet G, Jones RN. Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacterial isolated from European medical centers (2005–2007). J Chemother. 2009;21:500–506

PII: S0924-8579(10)00149-4

doi: 10.1016/j.ijantimicag.2010.03.016

International Journal of Antimicrobial Agents
Volume 36, Issue 1 , Pages 28-32 , July 2010

Article Tools